Ambit Biosciences Priced, Nasdaq: AMBI.XX
Developing small molecule therapeutics for the treatment of acute myeloid leukemia.
Industry: Health Care
First Day Return: -7.6%
| IPO Data | |
|---|---|
| IPO Date | 05/15/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $65 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2000 |
| Employees at IPO | 45 |
| Website www.ambitbio.com | |
Ambit Biosciences (AMBI.XX) Performance
